drug_type
RELEVANT_DRUG
intervention_type
Biologic (cellular immunotherapy; autologous CAR T cells)
drug_description
Autologous dual-target CAR T-cell therapy engineered to express CARs against BCMA and CD19; upon antigen engagement, T cells activate and kill BCMA+ plasma cells and CD19+ B cells to treat relapsed/refractory POEMS syndrome.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with dual chimeric antigen receptors targeting BCMA and CD19. Upon antigen binding, CAR signaling activates the T cells to proliferate and mediate cytotoxicity (perforin/granzyme, cytokine release), eliminating BCMA+ plasma cells and CD19+ B cells to deplete pathogenic clones in relapsed/refractory POEMS syndrome.
drug_name
KQ-2003
nct_id_drug_ref
NCT06518876